Next-Generation Antibody Companies Ink New Partnership Deals — Plus, 2 Sells
In biotechnology, one way to get a feel for a new therapeutic platform's potential for success is relationships. A really promising platform will generally attract the attention of other players who want a piece of the action.
Big Pharma has essentially “pharmed out” a lot of the drug discovery and development it used to do with emerging biotech companies. But if one of the new upstarts is truly promising in the opinion of the experts working at these companies, a couple of things can happen. One is a partnership, either on an existing drug under development at the junior company or for a collaboration to use that company's technology to develop a drug that doesn't exist yet. The second thing, of course, is an outright buyout of the smaller firm.
You Must Be A Subscriber To View This Content.
If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication below and get access today!
Technology Profits Confidential
With new technologies in mobile computing, biotechnology and 3-D printing, it’s nearly impossible to keep up with the throngs of new innovation and still be able to forecast which companies are set to profit. Technology Profits Confidential is your one-stop shop for the companies of tomorrow’s technology… and how you can profit from them.